Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19
Jie Ma, Peng Xia, Yangzhong Zhou, Zhengyin Liu, Xiang Zhou, Jinglan Wang, Taisheng Li, Xiaowei Yan, Limeng Chen, Shuyang Zhang, Yan Qin, Xuemei Li, Jie Ma, Peng Xia, Yangzhong Zhou, Zhengyin Liu, Xiang Zhou, Jinglan Wang, Taisheng Li, Xiaowei Yan, Limeng Chen, Shuyang Zhang, Yan Qin, Xuemei Li
No abstract availableKeywords: Blood purification; Critically ill COVID-19; Cytokine storm; IL-6; Plasma exchange.
Conflict of interest statement
Declaration of Competing Interest All other authors declare no competing interests.
Figures
The effect of blood purification therapy on inflammation markers and lymphocytes.The values of CRP, IL-6 and lymphocyte number were normalized, with reference to the first day of blood purification therapy (D1 in the figure). The dotted lines represented the data when patients were not on therapy, while the solid lines were data during the therapy.
References
- Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 Feb;28
- Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020 Feb;24
- Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020 Mar 13 doi: 10.1001/jamainternmed.2020.0994he.
- Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507–513.
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.
- Xu X., Han M., Li T., Sun W., Wang D., Fu B. Effective treatment of severe COVID-19 patients with Tocilizumab. ChinaXiv. 2020 202003.00026.
- Schwindenhammer V., Girardot T., Chaulier K., Gregoire A., Monard C., Huriaux L. oXiris(R) use in septic shock: experience of two French centres. Blood Purif. 2019;47(Suppl. 3):1–7.
- Bucciarelli S., Espinosa G., Cervera R., Erkan D., Gomez-Puerta J.A., Ramos-Casals M. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006 Aug;54(8):2568–2576.
- Monard C., Rimmele T., Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purif. 2019;47(Suppl. 3):1–14.
Source: PubMed